Bridging Gaps Between Formulation Development And Regulatory Expectations: Hidden Failure Modes In Generic Submissions

Rafał Łunio

Pharmaceutical research and development professional, Medical University of Gdańsk

*Corresponding Author Rafał Łunio, Pharmaceutical research and development professional, Medical University of Gdańsk, Email: rafal.lunio@gmail.com

Abstract

Generic drug development is often perceived as a technically predictable process based on pharmaceutical equivalence, bioequivalence, and compliance with established regulatory requirements. In practice, however, many development programs encounter regulatory deficiencies, delayed approvals, repeated questions, or late-stage operational barriers despite apparently acceptable formulation performance. These difficulties frequently do not arise from a single failed experiment or an isolated technical weakness. Rather, they reflect hidden inconsistencies between formulation development, process understanding, analytical strategy, stability interpretation, and the scientific narrative presented in the regulatory dossier.

This perspective article examines common development-regulatory disconnects observed in generic pharmaceutical development. The discussion focuses on formulation rationale gaps, process development inconsistencies, analytical and stability strategy weaknesses, fragmented common technical document narratives, and the difference between submission readiness and true launch readiness. Particular attention is given to the way in which technically generated data may lose regulatory value when they are not connected through a coherent scientific argument. The article also considers organizational contributors to these problems, including silo-based development models, late regulatory involvement, weak cross-functional ownership, and timeline-driven decision-making.

A practical framework for integrated development-regulatory alignment is proposed. The framework emphasizes early regulatory positioning, explicit formulation rationale, linkage between critical quality attributes and process parameters, risk-based analytical justification, structured common technical document storytelling, and lifecycle-oriented launch readiness assessment. The article argues that regulatory success in generic drug development should be built during development rather than repaired during dossier compilation. A stronger integration of pharmaceutical science, regulatory strategy, and operational readiness may improve submission quality, reduce avoidable deficiencies, and support more reliable access to generic medicines.